Enzymatica AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Enzymatica AB (publ) Stock Forecast and Price Target
Given the average yearlong price target of kr0.41 provided by prominent analysts over the past few months, there is a potential downside of approximately -86.01% from the last closing price in May, 2024 for Enzymatica AB (publ)'s stock if it is reached. This estimation is based on a high estimate of kr0.50 and a low estimate of kr0.31. If interested in ENZY stock, you may also want to consider its competitors.
-86.01% Downside
Enzymatica AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
Enzymatica AB (publ)'s Price has grown in the last four years, jumping from kr0.00 to kr0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach kr3.11 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CAMX Stock Forecast | Camurus AB (publ) | Outperform |
6
|
kr494.40 | Buy/Sell | kr471.33 | 19.34% |
| RECI B Stock Forecast | Recipharm AB (publ) | - |
15
|
kr232.00 | Buy/Sell | kr232.00 | -100.00% |
| BIOG B Stock Forecast | BioGaia AB (publ) | Buy |
18
|
kr113.20 | Buy/Sell | kr140.00 | 23.67% |
| SECARE Stock Forecast | Swedencare AB (publ) | Outperform |
16
|
kr56.35 | Buy/Sell | kr50.00 | 18.90% |
| CALTX Stock Forecast | Calliditas Therapeutics AB (pu... | Outperform |
10
|
kr108.70 | Buy/Sell | kr217.20 | 84.45% |
Enzymatica AB (publ) Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Enzymatica AB (publ) has seen a decline in its Revenue, from kr111.25M to kr50.90M – a 54.25% decrease. According to the 2 analysts polled, in the next year, Enzymatica AB (publ)'s Revenue will fall by 79.45%, reaching kr10.46M. By 2030, professionals believe that Enzymatica AB (publ)'s Revenue will have decreased by 8.83%, falling to kr46.40M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EGTX Stock Forecast | Egetis Therapeutics AB (publ) | Outperform |
7
|
kr6.96 | Buy/Sell | kr11.10 | 72.41% |
| EQL Stock Forecast | EQL Pharma AB (publ) |
14
|
kr44.20 | Buy/Sell | kr0.00 | 8.60% | |
| CRNO B Stock Forecast | Cereno Scientific AB (publ) |
0
|
kr3.87 | Buy/Sell | kr1.90 | -50.90% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IBT B Stock Forecast | Infant Bacterial Therapeutics ... | - |
0
|
kr103.50 | Buy/Sell | kr0.00 | -100.00% |
| DMYD B Stock Forecast | Diamyd Medical AB (publ) |
9
|
kr10.70 | Buy/Sell | kr19.00 | 96.26% | |
| MOB Stock Forecast | Moberg Pharma AB (publ) |
7
|
kr36.86 | Buy/Sell | kr29.00 | -37.60% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ORX Stock Forecast | Orexo AB (publ) |
6
|
kr17.20 | Buy/Sell | kr25.50 | 33.72% | |
| IRLAB A Stock Forecast | IRLAB Therapeutics AB (publ) |
16
|
kr11.15 | Buy/Sell | kr59.00 | 406.28% | |
| RLS Stock Forecast | RLS Global AB (publ) | - |
0
|
kr4.98 | Buy/Sell | kr0.00 | -100.00% |
Enzymatica AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
Enzymatica AB (publ)'s EBITDA has increased by 392.98% In the last three years, going from kr-9.12M to kr-44.96M. In the following year, 1 experts forecast Enzymatica AB (publ)'s EBITDA will decrease by 100.22%, to kr100.00k. In 2030, professionals predict that Enzymatica AB (publ)'s EBITDA will decrease by 505.53%, to kr182.33M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACTI Stock Forecast | Active Biotech AB (publ) |
0
|
kr0.55 | Buy/Sell | kr2.00 | 245.45% | |
| INDEX Stock Forecast | InDex Pharmaceuticals Holding ... | Hold |
0
|
kr0.38 | Buy/Sell | kr0.56 | 42.11% |
| NNH Stock Forecast | New Nordic Healthbrands AB (pu... | - |
0
|
kr19.00 | Buy/Sell | kr0.00 | -100.00% |
Enzymatica AB (publ) EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Enzymatica AB (publ)'s EBIT has grown, increasing from kr-12.06M to kr-48.06M – a growth of 298.51%. According to 2 major analysts, Enzymatica AB (publ)'s EBIT will fall by 96.88% in the next year, reaching kr-1.50M. Professionals believe that By 2030, Enzymatica AB (publ)'s EBIT will fall to kr-15.63M– a 67.48% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALZCUR Stock Forecast | AlzeCure Pharma AB (publ) |
0
|
kr1.80 | Buy/Sell | kr14.50 | 622.22% | |
| PILA Stock Forecast | Pila Pharma AB (publ) | - |
0
|
kr1.31 | Buy/Sell | kr0.00 | -100.00% |
| ISOFOL Stock Forecast | Isofol Medical AB (publ) | - |
6
|
kr0.69 | Buy/Sell | kr0.77 | 11.59% |
Enzymatica AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
Enzymatica AB (publ)'s EPS has grown in the last four years, jumping from kr-0.01 to kr0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach kr0.00 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ERMA Stock Forecast | Enorama Pharma AB (publ) | - |
-14
|
kr2.97 | Buy/Sell | kr0.00 | -100.00% |
| ODI Stock Forecast | ODI Pharma AB (publ) | - |
0
|
kr6.45 | Buy/Sell | kr0.00 | -100.00% |
| PMED Stock Forecast | PEPTONIC medical AB (publ) | - |
4
|
kr0.06 | Buy/Sell | kr0.79 | -100.00% |
.jpg)